LIANOS ACKERT

# Opportunities

## COPD:

+ no approved biologc  options
+ early diagnosis is important

## IPF

2 competitors 
+ early diagnosos
+ tolerability
+ trail enrollment is quite slow

---

SPAEKER 2

COPD | IPF

Fipaxalparant (LPAR1 SM)

